Anteris Technologies Presents Data from 100 DurAVR® THV Patients at PCR London Valves

Core Viewpoint - Anteris Technologies Global Corp. announced positive 30-day clinical outcomes for its DurAVR® Transcatheter Heart Valve (THV) in patients with severe aortic stenosis and small aortic annuli, highlighting its potential for commercialization and improved patient outcomes [1][4][7]. Group 1: Clinical Outcomes - The DurAVR® THV showed single-digit mean gradients and large effective orifice areas (EOAs), with no moderate or severe paravalvular leaks and no valve-related mortality, achieving 97% freedom from moderate or severe prosthesis-patient mismatch (PPM) [1][10]. - The pooled analysis included 100 patients from the ongoing EMBARK study and early feasibility studies, focusing on those with small aortic annuli treated with the DurAVR® THV [6][10]. - The technical success rate was 100% in the last 50 consecutive patient implants, indicating high rates of technical and device success [10]. Group 2: Expert Commentary - Prof. Dr. Ole De Backer emphasized the favorable hemodynamic outcomes and low PPM rates, which are critical for patients with small annuli, suggesting a unique balance of benefits from the DurAVR® THV [4][5]. - Chris Meduri, M.D., noted the clinical relevance of achieving 97% freedom from moderate or severe PPM, particularly in small annuli patients where the risk is heightened [5]. Group 3: Future Prospects - The results from the 30-day outcomes align with the 1-year results presented at TCT, reinforcing confidence in the DurAVR® THV as a promising technology as the company advances towards commercialization [7]. - The global PARADIGM Trial will further evaluate the safety and effectiveness of the DurAVR® THV compared to existing transcatheter aortic valve replacements (TAVRs) [8].